CAS 1168091-68-6

GDC-0623

Description:

GDC-0623, also known by its chemical name, is a small molecule inhibitor primarily targeting the protein kinase BRAF, specifically the BRAF V600E mutation. This compound is part of a class of targeted therapies designed to interfere with the signaling pathways that promote cancer cell proliferation and survival. GDC-0623 exhibits high selectivity for BRAF, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The substance is typically explored in the context of treating various cancers, particularly melanoma, where BRAF mutations are prevalent. Its mechanism of action involves inhibiting the ATP-binding site of the BRAF protein, thereby blocking downstream signaling pathways that lead to tumor growth. In preclinical studies, GDC-0623 has shown promising results in reducing tumor size and improving survival rates in models of BRAF-mutant cancers. As with many investigational drugs, ongoing clinical trials are essential to fully understand its safety profile, optimal dosing, and potential side effects in human patients.

GDC-0623

CAS: 1168091-68-6

Formula: C₁₆H₁₄FIN₄O₃

Purity: %

Color and Shape: Solid

Molecular weight: 456.2102

Ref: IN-DA008TGD

GDC-0623

CAS: 1168091-68-6

GDC-0623

Purity: ≥98%

Molecular weight: 456.21g/mol

Ref: 54-BUP08286

GDC-0623

CAS: 1168091-68-6

Formula: C₁₆H₁₄FIN₄O₃

Molecular weight: 456.22

Ref: 4Z-G-056001

GDC-0623

CAS: 1168091-68-6

GDC-0623 (RG 7421) is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

Formula: C₁₆H₁₄FIN₄O₃

Purity: 98.95% - 99.02%

Color and Shape: Solid

Molecular weight: 456.21

Ref: TM-T6843

GDC 0623

CAS: 1168091-68-6

Inhibitor of MEK kinases

Formula: C₁₆H₁₄FIN₄O₃

Purity: Min. 95%

Molecular weight: 456.21 g/mol

Ref: 3D-FG103137